

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1828
Policy Title	Bendamustine for relapsed/refractory classical Hodgkin lymphoma (all ages)
Clinical Reference Group	Chemotherapy Clinical Reference Group
Which stakeholders were contacted to be involved in policy development?	<p>The draft clinical commissioning policy statement was sent to the following groups for comment:</p> <ul style="list-style-type: none"> • Chemotherapy Clinical Reference Group (CRG); and • Registered stakeholders for the Chemotherapy CRG.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	<p>All of the relevant Royal Colleges and professional societies are represented on the Chemotherapy CRG. These include:</p> <ul style="list-style-type: none"> • British Oncology Pharmacy Association; • Royal College of Pathologists; and • British Society for Haematology. <p>Named representatives for each of these organisations were sent copies of the draft policy statement and invited to provide comment.</p>
Which stakeholders have actually been involved?	No responses were received from relevant Royal Colleges or professional societies. However, thirteen responses were received from registered stakeholders.
Explain reason if there is any difference from previous question	Not applicable.
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that	None identified.

<p>have yet to be engaged. Indicate why?</p>	
<p>How have stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy statement was distributed to stakeholders via email for a two week period of stakeholder testing.</p> <p>Stakeholders were asked to submit responses via email, using a standard response and in line with NHS England's standard processes for developing clinical commissioning policy.</p> <p>Stakeholder testing asked the following questions:</p> <ul style="list-style-type: none"> • Do you support the proposals within the policy statement? • Do you have any further comments on the proposal? • If Yes (to question 2), please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial 'sense check'. • Please declare any conflict of interests relating to this document or service area.
<p>What has happened or changed as a result of their input?</p>	<p>No changes have been made to the policy statement proposition as a result of feedback.</p> <p>There were thirteen responses to stakeholder testing of which three respondents actively supported the policy. The remaining respondents ten respondents raised the following issues:</p> <ul style="list-style-type: none"> • The evidence presented, although limited, appears to have efficacy and effectiveness in treating the disease. Additional papers believed to demonstrate the efficacy of the treatment were submitted by four respondents; • Bendamustine is now generic and therefore it is unlikely that large randomised control trials will be set-up in the future; and • As a generic medicine, the costs of bendamustine are now relatively small making this treatment inexpensive. <p>The decision to proceed for not routine commissioning was based on a review of evidence presented alongside the original Preliminary Policy Proposal. Budget impact is not considered at this stage. The Clinical Panel considered the</p>

	<p>evidence to be insufficient to support a routine commissioning position and, furthermore, could be considered to be experimental in some circumstances. The additional evidence submitted by stakeholders has been reviewed and it is considered that it is of low quality and does not materially impact the policy statement proposition (see Evidence Report).</p> <p>The Programme of Care does recognise the potential benefit of using bendamustine for this indication and therefore would support further research being undertaken to assess the effectiveness of treatment.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>Stakeholders will be notified when the final policy proposition is published.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Not applicable.</p>